Repligen Corporation
176.93USD
-1.7800 (-1.00%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on RGEN.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 801.5M | 632.4M | 634.4M | 738.3M | 836.3M | 1.1B |
| Q1 | 206.4M | 165.4M | 153.2M | 169.2M | 194.3M | — |
| Q2 | 207.6M | 159.2M | 158.8M | 182.4M | 204.1M | — |
| Q3 | 200.7M | 141.2M | 154.9M | 188.8M | 206.7M | — |
| Q4 | 186.8M* | 166.6M* | 167.5M* | 197.9M* | 233.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | .003 | .001 | -.000 | .001 | 2.06 | 2.70 |
| Q1 | .001 | .000 | .000 | .100 | .150 | — |
| Q2 | .001 | .000 | .000 | .259 | .090 | — |
| Q3 | .001 | .000 | -.000 | .000 | .463 | — |
| Q4 | .847* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.291* |
| -.605* |
| .235* |
| .564 |
| — |
Debt level and coverage